Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Depreciation and Depletion (2020 - 2024)

Immuneering's Depreciation and Depletion history spans 5 years, with the latest figure at $86116.0 for Q4 2024.

  • On a quarterly basis, Depreciation and Depletion fell 4.05% to $86116.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $355807.0, a 10.22% increase, with the full-year FY2024 number at $355807.0, up 10.22% from a year prior.
  • Depreciation and Depletion came in at $86116.0 for Q4 2024, down from $88949.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $90533.0 in Q2 2024, with the low at $5656.0 in Q3 2020.
  • Historically, Depreciation and Depletion has averaged $52121.7 across 5 years, with a median of $68075.0 in 2022.
  • Biggest five-year swings in Depreciation and Depletion: skyrocketed 468.33% in 2022 and later decreased 4.05% in 2024.
  • Year by year, Depreciation and Depletion stood at $7449.0 in 2020, then skyrocketed by 98.89% to $14815.0 in 2021, then soared by 418.81% to $76862.0 in 2022, then rose by 16.77% to $89754.0 in 2023, then decreased by 4.05% to $86116.0 in 2024.
  • Business Quant data shows Depreciation and Depletion for IMRX at $86116.0 in Q4 2024, $88949.0 in Q3 2024, and $90533.0 in Q2 2024.